You are here

Nefazodone HCl Approved by FDA

CORONA, Calif., Sept. 16 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, announced today that it has received final approval from the United States Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for nefazodone hydrochloride tablets in the 100 mg, 150 mg, 200 mg and 250 mg strengths. Nefazodone hydrochloride is the generic equivalent of Bristol-Myers Squibb's Serzone® and is indicated for the treatment of depression. For the 12-months ending June 2003, Serzone® had sales of approximately $220 million for all strengths, according to IMS data. Watson's nefazodone hydrochloride product will be launched immediately, making it the Company's 21st product launched in 2003.

Source: Watson Pharmaceuticals, Inc.

Recent Headlines

Scenesse is new treatment for people with rare, painful light sensitivity disease
Humira, Rituxan top list of drugs that added $5.1 billion to nation's health care bill
Lower court rulings cleared the way for generic versions of the MS drug
Maryland man wins lawsuit that alleges that the company's antipsychotic caused his gynecomastia
Antidepressants, ADHD meds are also used to self-poison
Study lists steps that could save close to $300 billion a year
While many victims used THC, the cause remains elusive
Descovy joins Truvada, another Gilead product, in the HIV prophylaxis market
Data show PTC Therapeutics drug preserves lung function